Effects of intravenously and orally administered solifenacin succinate (YM905) on carbachol-induced intravesical pressure elevation and salivary secretion in mice.

Effects of intravenously and orally administered solifenacin succinate (YM905) on carbachol-induced intravesical pressure elevation and salivary secretion in mice. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Effects of intravenously and orally administered solifenacin succinate (YM905) on carbachol-induced intravesical pressure elevation and salivary secretion in mice. Abstract Text:

Hiroko Okutsu,Yukiko Noguchi,Akiyoshi Ohtake,Masanori Suzuki,Shuichi Sato,Masao Sasamata,Hiroko Okutsu,Yukiko Noguchi,Akiyoshi Ohtake,Masanori Suzuki,Shuichi Sato,Masao Sasamata,Hiroko Okutsu,Yukiko Noguchi,Akiyoshi Ohtake,Masanori Suzuki,Shuichi Sato,Masao Sasamata,

Solifenacin succinate is a novel muscarinic receptor antagonist used for the treatment of overactive bladder (OAB). We investigated the effects of solifenacin by oral and intravenous administration on carbachol (CCh)-induced intravesical pressure (IVP) elevation and compared its efficacy with that on CCh-induced salivary secretion in anesthetized mice. Additionally, we also investigated the change in effects between single and repeated oral administration of solifenacin on CCh-induced IVP elevation. Results showed that intravenous administration of solifenacin dose-dependently inhibited the IVP elevation and salivary secretion. The ratio of bladder response to salivary response (ratio of ID(50) values) was 2.1. Oral administration of solifenacin (0.3-30 mg/kg) also inhibited CCh-induced IVP elevation and salivary secretion. Although inhibition of these responses by solifenacin (10, 30 mg/kg) was comparable at early time points (0.5 and 1 h after administration at 10 mg/kg and 0.5 to 2 h after administration at 30 mg/kg), inhibition of CCh-induced IVP elevation was stronger at later time points (2 to 8 h after administration at 10 mg/kg and 4 to 24 h after administration at 30 mg/kg). No significant difference in ID(50) values for IVP elevation was observed between single and repeated (11 d) oral administration of solifenacin (1-30 mg/kg), suggesting no change in efficacy on chronic administration. In conclusion, intravenous and oral solifenacin inhibits CCh-induced IVP elevation more potently than salivary secretion. These results provide further evidence for the clinical use of solifenacin as a promising therapeutic drug for OAB with a low incidence of dry mouth.

Effects of intravenously and orally administered solifenacin succinate (YM905) on carbachol-induced intravesical pressure elevation and salivary secretion in mice. Publishing Authors By Initials

H Okutsu,Y Noguchi,A Ohtake,M Suzuki,S Sato,M Sasamata,H Okutsu,Y Noguchi,A Ohtake,M Suzuki,S Sato,M Sasamata,H Okutsu,Y Noguchi,A Ohtake,M Suzuki,S Sato,M Sasamata,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Effects of intravenously and orally administered solifenacin succinate (YM905) on carbachol-induced intravesical pressure elevation and salivary secretion in mice. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Biological & pharmaceutical bulletin

VOLUME: 30

Page Numbers: 2324-7

Journal Abbreviation: Biol. Pharm. Bull.

ISSN: 0918-6158

DAY: 6

MONTH: Dec

YEAR: 2007

Effects of intravenously and orally administered solifenacin succinate (YM905) on carbachol-induced intravesical pressure elevation and salivary secretion in mice. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9311984

Effects of intravenously and orally administered solifenacin succinate (YM905) on carbachol-induced intravesical pressure elevation and salivary secretion in mice. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Effects of intravenously and orally administered solifenacin succinate (YM905) on carbachol-induced intravesical pressure elevation and salivary secretion in mice. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Effects of intravenously and orally administered solifenacin succinate (YM905) on carbachol-induced intravesical pressure elevation and salivary secretion in mice.

AFFILIATION: Pharmacology Research Labs., Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan. hiroko.okutsu@jp.astellas.com

Country: Japan

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Biol Pharm Bull

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Effects of intravenously and orally administered solifenacin succinate YM905 on carbachol-induced intravesical pressure elevation and salivary secretion in mice Related Publications

• Effect of YM598, a selective endothelin ETA receptor antagonist, on endothelin-1-induced bone formation.
• Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.
• Effects of intravenously and orally administered solifenacin succinate (YM905) on carbachol-induced intravesical pressure elevation and salivary secretion in mice.
• In vivo study on the effects of alpha(1)-adrenoceptor antagonists on intraurethral pressure in the prostatic urethra and intraluminal pressure in the vas deferens in male dogs.